NeuroPro Therapeutics

Focus: NeuroPro Therapeutics is a pre-revenue biotechnology company focused on neurological compounds, headquartered in Yachats, OR. The company is in early-stage clinical development with a focused pipeline targeting epilepsy indications.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About NeuroPro Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow NeuroPro Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NPT 2042

Photosensitive Epilepsy

Phase 1

Clinical Trials (1)

NCT06525649A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042

Phase 1

Help build intelligence for NeuroPro Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a focused neuro biotech with early-stage programs in epilepsy, a large unmet need market
Active pipeline with 4 ongoing clinical trials (3 Phase 1, 1 Phase 2) provides clinical development learning opportunities
Opportunity to shape company culture and build institutional knowledge in a small, mission-driven organization

Watch Out For

Pre-revenue stage means no financial cushion; cash runway and funding trajectory are critical unknowns
Currently zero active job openings and minimal disclosed employee count signal either a very small team or hiring freeze
Absence of published data, recent news, or patent disclosures limits visibility into scientific momentum and competitive position

Generated by Claude from NeuroPro Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NPT 2042

Epilepsy

Phase 1

Clinical Trials (1)

NCT07222878Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

Phase 1

NPT 2042

Epilepsy

Phase 1

Clinical Trials (1)

NCT05503511Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

Phase 1

NPT 2042

Epilepsy, Generalized

Phase 2

Clinical Trials (1)

NCT06769659A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

4 pipeline

Marketed

Pipeline